DPH1 and DPH2 variants that confer susceptibility to diphthamide deficiency syndrome in human cells and yeast models
Disease Models & Mechanisms · 2023
DOI: 10.1242/dmm.050207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2023. Verfasst von Koray Ütkür und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Biologie, Fachgebiet Mikrobiologie , Universität Kassel, 34132 Kassel, Germany. Hauptthemen laut MEDLINE: Saccharomyces cerevisiae, Saccharomyces cerevisiae Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Kassel, Deutsche Forschungsgemeinschaft, Roche Diagnostics GmbH.
Abstract (Originalsprache)
The autosomal-recessive diphthamide deficiency syndrome presents as intellectual disability with developmental abnormalities, seizures, craniofacial and additional morphological phenotypes. It is caused by reduced activity of proteins that synthesize diphthamide on human translation elongation factor 2. Diphthamide synthesis requires seven proteins (DPH1-DPH7), with clinical deficiency described for DPH1, DPH2 and DPH5. A limited set of variant alleles from syndromic patients has been functionally analyzed, but databases (gnomAD) list additional so far uncharacterized variants in human DPH1 and DPH2. Because DPH enzymes are conserved among eukaryotes, their functionality can be assessed in yeast and mammalian cells. Our experimental assessment of known and uncharacterized DPH1 and DPH2 missense alleles showed that six variants are tolerated despite inter-species conservation. Ten additional human DPH1 (G113R, A114T, H132P, H132R, S136R, C137F, L138P, Y152C, S221P, H240R) and two DPH2 (H105P, C341Y) variants showed reduced functionality and hence are deficiency-susceptibility alleles. Some variants locate close to the active enzyme center and may affect catalysis, while others may impact on enzyme activation. In sum, our study has identified functionally compromised alleles of DPH1 and DPH2 genes that likely cause diphthamide deficiency syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Biologie, Fachgebiet Mikrobiologie , Universität Kassel, 34132 Kassel, Germany.
- Roche Pharma Research and Early Development (pRED), Large Molecule Research, Roche Innovation Center Munich, 82377 Penzberg, Germany.
ORCID-Profile: Raffael Schaffrath, Ulrich Brinkmann
Förderung
- Universität Kassel
- Deutsche Forschungsgemeinschaft
- Roche Diagnostics GmbH
Zitieren
APA
Ütkür, K., Mayer, K., Khan, M., Manivannan, T., Schaffrath, R., & Brinkmann, U. (2023). DPH1 and DPH2 variants that confer susceptibility to diphthamide deficiency syndrome in human cells and yeast models. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.050207
Vancouver
Ütkür K, Mayer K, Khan M, Manivannan T, Schaffrath R, Brinkmann U. DPH1 and DPH2 variants that confer susceptibility to diphthamide deficiency syndrome in human cells and yeast models. Disease Models & Mechanisms. 2023. doi:10.1242/dmm.050207
BibTeX
@article{tkr2023,
author = {Ütkür, Koray and Mayer, Klaus and Khan, Maliha and Manivannan, Thirishika and Schaffrath, Raffael and Brinkmann, Ulrich},
title = {DPH1 and DPH2 variants that confer susceptibility to diphthamide deficiency syndrome in human cells and yeast models},
journal = {Disease Models & Mechanisms},
year = {2023},
doi = {10.1242/dmm.050207}
}
EUVIMED